Cellectis S.A. (CLLS)
About Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $307.9M
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $307.9M
- Shares outstanding
- 108.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 25, 2015
Cellectis S.A. (CLLS) Stock Price
- Trading 47% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Cellectis S.A..
Write a review
News about Cellectis S.A.
News & sentiment via Polygon.io
Cellectis S.A.: frequently asked questions
Is Cellectis S.A. an American company?
Cellectis S.A. is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is Cellectis S.A. publicly traded?
Yes — Cellectis S.A. is a publicly traded company. Its stock trades under the ticker symbol CLLS on the NASDAQ.
What does Cellectis S.A. do?
Cellectis S.A. is an American Pharmaceuticals company in the Health & Beauty sector.
